Market capitalization | $37.14m |
Enterprise Value | $32.60m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 18.11 |
P/S ratio (TTM) P/S ratio | 20.63 |
P/B ratio (TTM) P/B ratio | 11.72 |
Revenue growth (TTM) Revenue growth | -47.53% |
Revenue (TTM) Revenue | $1.80m |
As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.
1 Analyst has issued a forecast Dyadic International, Inc.:
1 Analyst has issued a forecast Dyadic International, Inc.:
Jun '24 |
+/-
%
|
||
Revenue | 1.80 1.80 |
48%
48%
|
|
Gross Profit | 0.90 0.90 |
48%
48%
|
|
EBITDA | -8.04 -8.04 |
4%
4%
|
EBIT (Operating Income) EBIT | -8.04 -8.04 |
4%
4%
|
Net Profit | -7.74 -7.74 |
9%
9%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Dyadic International, Inc. engages in developing a gene expression platform for producing commercial quantities of industrial enzymes and other proteins. It focuses on further improving and applying its proprietary C1 technology, which is used in the discovery, development, and manufacture of biologic medicines and vaccines. The company was founded by Mark A. Emalfarb in 1979 and is headquartered in Jupiter, FL.
Head office | United States |
CEO | Mark Emalfarb |
Founded | 1979 |
Website | www.dyadic.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.